Daily Recap - WEDNESDAY
Join panelists Drs. Janet Pope, Richard Conway, Meral El Ramahi and Jack Cush recap the best presentations presented on day four of the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →What's hot
View all perspectives
What's Hot
EXXELERATE Study: Do High RF Titers Impact Response to TNF Inhibitors?
Dr. Jonathan Kay discusses abstract 2148 with Dr. Josef Smolen at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Bimekizumab in Active AS: 5 Year Study
Dr. Atul Deodhar reporting on abstract 0519 from the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Cannabinoid Receptor in RA Patients
Dr. Arthur Kavanaugh discusses abstract 0025 at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Treatments in SpA
Dr. Rachel Tate and Dr. Catherine Blakewell discuss treatment options patients in spondyloarthritis at the 2023 ACR Convergence meeting in San Diego, CA. Abstracts discussed include 0520, 0530, 0521 and 0529.
Watch video →
PR3+ in Lupus Nephritis
Dr. Jack Cush discusses abstract 2427 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Simulated Trials to Counter ORAL Survelliance
Dr. Jack Cush and Dr. Janet Pope at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Difficult to Treat axSpA
Dr. Peter Nash reports on abstracts 0514 and 0538 from the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Window of Opportunity in PsA
Dr. Peter Nash discusses a study that looks at the window of opportunity for treatment of PsA at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
TMP SMX Prophylaxis in GPA
Dr. Jack Cush and Dr. Janet Pope discuss abstract 1584 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
The FOREMOST Study: Apremilast in PsA
Dr. Peter Nash reports on abstract 1691 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
The SMART Study: Split Dose Oral Methotrexate
Dr. Jack Cush discusses abstract 1583 presented at the 2023 ACR Convergence meeting in San Diego.
Watch video →
Real World Experience with PEXIVAS Low Steroid Taper
Dr. Mike Putman discusses abstract 0725 with Dr. Sophie Nagle at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Cancer and TNF inhibitors
Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. An oral presentation by Suarez-Almazor et al provided more supportive data on using TNFi in this population.
Read more →
#ACRbest Abstracts – Day 2
Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media. Here are RheumNow's #ACRbest abstract reports from Monday, November 13, 2023 at #ACR23, covering The Great Debate, SGLPT2 inhibitors in SLE, the SMART Study of MTX, TMP/SMX Prophylaxis, RA-ILD & TNF Inhibitors, cancer research and more.
Read more →
Effects of Apremilast on Cardiometabolic Effects in PsA
Dr. Peter Nash discusses abstract 1414 at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
An Interview with Kevin Winthrop: Three Questions About COVID 19
Drs. Jack Cush and Kevin Winthrop discuss COVID 19 at 2023 ACR Convergence in San Diego, CA.
Watch video →
Biologics as First-line Therapy for PMR and GCA?
Dr. Eric Dein talks with Dr. Philip Seo, one of two panelists for the Great Debate: Should PMR and GCA Be Treated with Advanced Therapies at Disease Onset? at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
David Liew drdavidliew
2 years ago
COVID boosters in RA patients:
getting the job done (versus healthy controls, irrespective of non-withheld DMARDs excluding ritux)
@UChicagoMed #ACR23 ABST0416 @RheumNow https://t.co/HVRjC4dauw
Janet Pope
2 years ago
I’m not TYK’ed! Another TYK2 #TAK-279 in #PsA RCT. Yup it works in ballpark of other PsA #Rx. #PASI75 45.7%. No obvious dose response w 15 and 30 mg daily but more #acne at higher dose. #ACR23 @ACRheum @RheumNow poster L12 Where to use vs #Deucravitinib? Too early to say as Ph2 https://t.co/nMkgOlUf6s
sheila
2 years ago
Does knowing ischemic stroke subtypes among SLE patients matter?
This study by Hopia et al 👉54% of ischemic strokes in 56 SLE pts were APS/aPL & cardioembolic origin (accdg to TOAST) & +assoc with STAT4 gene.
#ACR23 ABST0579 @RheumNow https://t.co/Ut8QPpQNQp
David Liew drdavidliew
2 years ago
Can a picture tell a RA swollen joint?
(would be super useful for telehealth/remote monitor if so)
It's not prime time yet, but following with interest:
using photos to pick up on skin folds/joint swelling
Fascinating, but let's see it vs MRI, clinical
#ACR23 ABST0402 @RheumNow https://t.co/TFKiD5J4c8
TheDaoIndex KDAO2011
2 years ago
We gotta do better! Reproductive health counseling is poorly done- only a third rheumatologists surveyed ask pts about reproductive health: sexual activity, pregnancy desire, contraception. Abstr#0162 @_michgarcia @rheumnow #ACR23 https://t.co/r9tewu2I9N
Robert B Chao, MD
2 years ago
Smartwatches to measures axSpA activity?
Upadacitinib use in axSpA INCREASED physical activity based on a wearable medical device step count, especially in those who were originally sedentary.
@RheumNow #ACR23 Abs#0530
#ACRbest https://t.co/oOFiQwMFZ6
sheila
2 years ago
SLE pts with +aCL IgG/IgM and LA had higher risk of developing atherosclerotic CVD accdg to this prospective study by Ding et al.
. . .
🧐Again, SLE pts have ⬆️CV risk so always risk stratify and intervene early.
#ACR23 ABST0552 @RheumNow https://t.co/QhttQZzp8G
Meral K. El Ramahi, MD MeralElRamahiMD
2 years ago
Year in Review by Dr. P Seo
NORD-STAR trial:
⭐️Abatacept or Certolizumab >> Tociluzumab > triple therapy in tx of 812 early RA patients based on clinical & radiographic results
➡️tx-naive, all got MTX
➡️mod-sev dz activity
➡️randomized to 48 wks therapy
#ACR23 @RheumNow https://t.co/vy2uYuyOse
Mike Putman EBRheum
2 years ago
Interesting question... but feels like some time related bias or perhaps confounding?
Seems implausible that MTX & biologic would be protective for PsO & harmful for PsA
@RheumNow #ACR23 Abstr 0498 https://t.co/pSRoLHRTAm
David Liew drdavidliew
2 years ago
NAFLD a real issue in RA
Does DMARD choice matter?
National Taiwanese data
newly dx RA n=41791
HCQ reduced NAFLD risk: adjHR 0.75
(other RF: obesity, NSAIDs, even low-dose PNL; but not DM, MTX)
Can HCQ improve liver health in RA?
Authors: ?adiponectin
#ACR23 ABST0396 @RheumNow https://t.co/9VMJpImFKs
Robert B Chao, MD
2 years ago
C-VIEW study on certolizumab use in preventing anterior uveitis in high risk pts with axSpA.
All pts were B27+ w/ at least one episode of anterior uveitis
Uveitis flares lower in certolizumab group compared to non-bDMARD use
@RheumNow #ACR23 Abs#0524 https://t.co/CfnhzStBMv
sheila
2 years ago
This study by Munoz-Grajales et al show that the analyte S100A8/A9 (highest AUC) was able to differentiate between SLE pts with cognitive impairment and those without.
. . .
Interesting findings.
More data needed to confirm and explain why it is so.
#ACR23 ABST0558 @RheumNow https://t.co/LcF6s2qgNr
Dr. Antoni Chan
2 years ago
PROs are useful for tracking RA disease activity over time outside of the clinic setting for patients initiating new treatments without clinician-derived measures. Correlations in follow-up CDAI and PROs were 0.38 – 0.56, Nowell Abst#0380 #ACR23 @RheumNow https://t.co/LepCZ7sPY8 https://t.co/UYcZzIFEsx
Janet Pope
2 years ago
#CV risk in #AxSpA in Korean population study N=71001, age 42, 71%M but 16% #MTX, 58% #SSZ. #TNFi vs none 30% less CVE. IL17 NO CV reduction but ?confounded by line of #Rx and v large N for TNFi. Study stated PRIOR to IL17i approval #ACR23 @ACRheum @RheumNow L11 poster ?Rx bias https://t.co/3Sft5KUlLa
Mike Putman EBRheum
2 years ago
Nice VA study evaluating risk of lung cancer w/respect to RA treatment strategies
Take home? No association. Aside from the (small risk) w/JAKi's, I think malignancy risks have been mostly overblown
@NamrataRheum @RheumNow ABST0453 #ACR23 https://t.co/lDz0nV1KHt
Poster Hall